Navigation Links
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Date:3/31/2008

er factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
3. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
9. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
10. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Second quarter overview: , Revenues of $53.9 million, ... Diluted EPS of $0.24, up 33% over last year,s ... revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... BEIJING, Aug. 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... the first fiscal quarter ended June 30, 2011 ("1Q ... 2011. The Company,s senior management will host ...
... N.J., Aug. 4, 2011 Omthera Pharmaceuticals, Inc., ... that Christian S. Schade will join the Company ... President and Chief Financial Officer, beginning in early ... experience as a public company financial executive in ...
Cached Medicine Technology:China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2011 on August 16, 2011 2Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer 2Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer 3
(Date:10/25/2014)... October 26, 2014 BioSkinLaser.Com, the leading ... most advanced and improved laser treatments for its customers. ... treatments like the lip enhancement treatment . It ... specific focus areas of each customer. , BioSkinLaser.Com has ... reduction NYC . The company cited that it created ...
(Date:10/25/2014)... October 25, 2014 Background: , In ... (CCAR). He is a pioneer in the field of establishing ... Connecticut's state treatment system and when he retired, he set ... while in public service. , 1. Where ... decisions concerning them? , 2. Can the recovery community ...
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... Randy Dotinga HealthDay ... As more genetic tests are developed that spot increased risks ... be more proactive about getting screened. But a new ... not change behavior: People who found out their genes doubled ... people with average risk to get screened. "It didn,t ...
Breaking Medicine News(10 mins):Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 2Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 3Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
... eating away from home,could put kids at higher risk for ... this month,s research journal "Obesity.", SDSU public health researcher ... of relatives, neighbors or friends once a week,or more is ... Youngsters who ate away from home often drank more sugar-sweetened,beverages ...
... Two scientists who helped explain how embryos develop and ... to receive the 2008 March of Dimes Prize in Developmental ... J. Tabin, PhD will share the 2008 March of Dimes ... of how hedgehog genes and their protein signals guide the ...
... extra iron for infants who don,t need it might delay ... supplement levels and could have huge implications for the baby ... of research show problems with lack of iron. For us ... unexpected," said Dr. Betsy Lozoff, University of Michigan research professor ...
... initiative, US and Canadian experts have developed a ... resources during times of pandemic outbreaks or other ... legally protecting clinicians who follow accepted protocols for ... during mass critical care events. The framework represents ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ("China ... Bulletin,Board: CSKI), a leading fully integrated pharmaceutical ... People,s Republic of China,("PRC"), today announced the ... for its diagnostic kits., Harbin First ...
... research suggests that high-risk women with breast cancer who do ... for developing a second breast cancer than previously thought. ... sentinel node biopsy be considered at the time of prophylactic ... findings? , The increased risk of developing breast cancer ...
Cached Medicine News:Health News:SDSU Study Reveals Eating at Friends and Family's Puts Kids at Higher Risk for Obesity 2Health News:March of Dimes awards $250,000 prize to leaders in understanding embryonic development 2Health News:Iron supplements might harm infants who have enough 2Health News:New disaster preparedness strategy announced 2Health News:New disaster preparedness strategy announced 3Health News:New disaster preparedness strategy announced 4Health News:China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits 2Health News:China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits 3Health News:Second breast cancer may be greater than thought for high-risk women without BRCA mutations 2
... DePuy 1 Gentamicin Bone Cement, a ... in the international market for over a ... antibiotic into cement. The premixed powder helps ... 1 Gentamicin Bone Cement provides the same ...
... 35 years, Palacos Bone Cement ... the gold standard in cemented ... introduction of,the Optivac system in ... provided thousands of physicians the ...
... Scanning Laser Doppler Flowmetry System ... Perfusion, ,The Heidelberg Retina Flowmeter uniquely ... laser scanning and laser Doppler flowmetry, ... that provides non-invasive two-dimensional mapping of ...
... Dosposable Easy Insertion/Removal ,The Mackool ... reliable support to the lens capsule ... phacoemulsification regardless of zonular status. ... disposable iris retractors), and removal is ...
Medicine Products: